This Monday, Bio-Thera Solutions and Dr. Reddy’s Laboratories SA announced that they had entered into commercialization and licensing agreements for proposed ustekinumab and golimumab ...

The overlap of biologics during medication switches is common in routine care of patients with IBD and isn’t linked to a ...

TNF inhibitors used in JAK-pot registries included adalimumab, etanercept, infliximab (Remicade), certolizumab pegol (Cimzia), and golimumab (Simponi). Besides tofacitinib, JAK inhibitors included ...

Prior to J&J Innovation, Marcella held key roles at Janssen’s Immunology Medical Affairs Department, where she supported the medical engagement, clinical feasibility, and launch strategies for ...

Biologics approved by the Food and Drug Administration (FDA) for managing ulcerative colitis include: Anti-TNF agents, such as Humira (adalimumab), Simponi (golimumab), Remicade (infliximab ...

There are currently four monoclonal antibodies available that are directed against TNF: infliximab, adalimumab, golimumab and certolizumab. All of these agents are efficacious in RA, with clinical ...

He noted that in the longer term, J&J 's sales of Simponi Aria (golimumab) continue to grow in rheumatoid arthritis. The company has noted that s J&J has also filed sirukumab in the US and EU ...

in 2012 and J&J’s Simponi (golimumab) in 2013. In Europe, these therapies were introduced between 2006 and 2013. The anti-TNF era was followed by the emergence of interleukin (IL) inhibitors ...

During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in ...